Zhang Chenyu, Ma Peixiang, Qin An, Wang Liao, Dai Kerong, Liu Yuanyuan, Zhao Jie, Lu Zuyan
School of Medicine, Shanghai University, Shanghai, China.
Clinical and Translational Research Center for 3D Printing Technology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Research (Wash D C). 2023 Oct 17;6:0220. doi: 10.34133/research.0220. eCollection 2023.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease accompanied by persistent multiarticular synovitis and cartilage degradation. The present clinical treatments are limited to disease-modifying anti-rheumatic drugs (DMARDs) and aims to relieve pain and control the inflammation of RA. Despite considerable advances in the research of RA, the employment of current clinical procedure is enormous, hindered by systemic side effect, frequent administration, tolerance from long-lasting administration, and high costs. Emerging immunoengineering-based strategies, such as multiple immune-active nanotechnologies via mechanism-based immunology approaches, have been developed to improve specific targeting and to reduce adverse reactions for RA treatments. Here, we review recent studies in immunoengineering for the treatment of RA. The prospect of future immunoengineering treatment for RA has also been discussed.
类风湿性关节炎（RA）是一种慢性炎症性自身免疫性疾病，伴有持续性多关节滑膜炎和软骨降解。目前的临床治疗仅限于改善病情抗风湿药（DMARDs），旨在缓解疼痛并控制类风湿性关节炎的炎症。尽管类风湿性关节炎的研究取得了相当大的进展，但目前临床治疗方法的应用存在诸多问题，受到全身副作用、频繁给药、长期给药产生的耐受性以及高成本的阻碍。基于免疫工程的新兴策略，如通过基于机制的免疫学方法的多种免疫活性纳米技术，已被开发用于改善类风湿性关节炎治疗的特异性靶向并减少不良反应。在此，我们综述了免疫工程治疗类风湿性关节炎的最新研究。还讨论了类风湿性关节炎免疫工程未来治疗的前景。
